CAPTRUST Financial Advisors
BBIO icon

CAPTRUST Financial Advisors’s BridgeBio Pharma BBIO Stock Holding History

CAPTRUST Financial Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$331K Buy
5,037
+351
+7% +$27.3K ﹤0.01% 2573
2026
Q2 		$349K Sell
4,686
-432
-8% -$30.3K ﹤0.01% 2459
2026
Q1 		$380K Buy
5,118
+1,404
+38% +$102K ﹤0.01% 2225
2025
Q4 		$284K Buy
+3,714
New +$244K ﹤0.01% 2289
2024
Q1 		– Sell
-25,997
Closed -$1.05M – 2192
2023
Q4 		$1.05M Sell
25,997
-4,273
-14% -$128K ﹤0.01% 1234
2023
Q3 		$798K Buy
30,270
+10,845
+56% +$308K ﹤0.01% 1334
2023
Q2 		$334K Buy
+19,425
New +$292K ﹤0.01% 1890
2022
Q3 		– Sell
-1,034
Closed -$9K – 2252
2022
Q2 		$9K Sell
1,034
-100
-9% -$836 ﹤0.01% 3787
2022
Q1 		$12K Buy
1,134
+573
+102% +$5.88K ﹤0.01% 3693
2021
Q4 		$9K Buy
561
+114
+26% +$4.82K ﹤0.01% 3762
2021
Q3 		$21K Buy
447
+268
+150% +$14.4K ﹤0.01% 3120
2021
Q2 		$11K Sell
179
-25
-12% -$1.43K ﹤0.01% 3483
2021
Q1 		$13K Buy
+204
New +$13.3K ﹤0.01% 3273

Other funds holding BBIO

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aisling Capital Management
Aisling Capital Management New York $299M AUM 39.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

CAPTRUST Financial Advisors's BBIO Position: Q3 2026 in Review

CAPTRUST Financial Advisors increased its BridgeBio Pharma (BBIO) stake by 7.5% in Q3 2026, buying an estimated $27.3K and bringing the position to 5,037 shares worth $331K. The position accounts for ﹤0.01% of the portfolio, ranked #2573.

CAPTRUST Financial Advisors first reported a position in BBIO in Q1 2021 and has held it in 13 quarters since. The position peaked at $1.05M in Q4 2023. 290 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.

  • CAPTRUST Financial Advisors held 5,037 shares of BridgeBio Pharma worth $331K as of Q3 2026.
  • CAPTRUST Financial Advisors bought 351 BridgeBio Pharma shares in Q3 2026, an estimated $27.3K.
  • BridgeBio Pharma made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q3 2026, its #2573 holding.
  • CAPTRUST Financial Advisors first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 13 quarters since.
  • CAPTRUST Financial Advisors's BridgeBio Pharma position peaked at $1.05M in Q4 2023.
  • 290 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.